Capecitabine Winthrop New Zealand - English - Medsafe (Medicines Safety Authority)

capecitabine winthrop

sanofi-aventis new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

CAPECITABINE INOVAMED 500 MG Israel - English - Ministry of Health

capecitabine inovamed 500 mg

inovamed ltd - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer.colorectal cancer: capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.advanced gastric cancer: capecitabine is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy.breast cancer combination therapy: capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.breast cancer monotherapy: capecitabine is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

CAPECITABINE INOVAMED 500 MG Israel - English - Ministry of Health

capecitabine inovamed 500 mg

inovamed ltd - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer.colorectal cancer: capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.advanced gastric cancer: capecitabine is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy.breast cancer combination therapy: capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.breast cancer monotherapy: capecitabine is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

APO-CAPECITABINE capecitabine 500 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-capecitabine capecitabine 500 mg tablet blister pack

arrotex pharmaceuticals pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; iron oxide yellow; titanium dioxide; lactose; colloidal anhydrous silica; methylcellulose; iron oxide red; hyprolose; croscarmellose sodium; hypromellose; macrogol 8000 - colon cancer,capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

CAPECITABINE AN capecitabine 500 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

capecitabine an capecitabine 500 mg film-coated tablet blister pack

juno pharmaceuticals pty ltd - capecitabine -

CAPECITABINE AN capecitabine 150 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

capecitabine an capecitabine 150 mg film-coated tablet blister pack

juno pharmaceuticals pty ltd - capecitabine -

CAPECITABINE Ireland - English - HPRA (Health Products Regulatory Authority)

capecitabine

fresenius kabi oncology plc - capecitabine - film coated tablet - 500 milligram - capecitabine

Capecitabine Cipla 150mg Film-coated Tablets Malta - English - Medicines Authority

capecitabine cipla 150mg film-coated tablets

cipla europe n.v. uitbreidingstraat 80, 2600 antwerp, belgium - capecitabine - film-coated tablet - capecitabine 150 mg - antineoplastic agents

Capecitabine Cipla 500mg Film-coated Tablets Malta - English - Medicines Authority

capecitabine cipla 500mg film-coated tablets

cipla europe n.v. uitbreidingstraat 80, 2600 antwerp, belgium - capecitabine - film-coated tablet - capecitabine 500 mg - antineoplastic agents

Capecitabine 150 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

capecitabine 150 mg film-coated tablets

fresenius kabi oncology plc - capecitabine - film-coated tablet - 150 milligram(s) - pyrimidine analogues; capecitabine